Kangdesai Medical Technology
Chengdu
About Kangdesai Medical Technology
Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrence and metastasis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $7.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2025)
- Website: cunde.com
- Phone: +86 028-69261055
Industries & Categories
Health Care, Medical, Medical Device, Pharmaceutical
Canonical: https://fsome.com/organization/kangdesai-medical-technology-19172 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.